• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic

tetano

Editor, Senior Moderator
Cell Rep


. 2025 Apr 1;44(4):115498.
doi: 10.1016/j.celrep.2025.115498. Online ahead of print. Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic

Luis M Molinos-Albert[SUP] 1 [/SUP], Rocío Rubio[SUP] 2 [/SUP], Carla Martín-Pérez[SUP] 2 [/SUP], Edwards Pradenas[SUP] 3 [/SUP], Cèlia Torres[SUP] 2 [/SUP], Alfons Jiménez[SUP] 4 [/SUP], Mar Canyelles[SUP] 2 [/SUP], Marta Vidal[SUP] 2 [/SUP], Diana Barrios[SUP] 5 [/SUP], Silvia Marfil[SUP] 3 [/SUP], Ester Aparicio[SUP] 3 [/SUP], Anna Ramírez-Morros[SUP] 6 [/SUP], Benjamin Trinité[SUP] 3 [/SUP], Josep Vidal-Alaball[SUP] 7 [/SUP], Pere Santamaria[SUP] 8 [/SUP], Pau Serra[SUP] 9 [/SUP], Luis Izquierdo[SUP] 10 [/SUP], Ruth Aguilar[SUP] 2 [/SUP], Anna Ruiz-Comellas[SUP] 11 [/SUP], Julià Blanco[SUP] 12 [/SUP], Carlota Dobaño[SUP] 13 [/SUP], Gemma Moncunill[SUP] 14 [/SUP]



Affiliations
Free article Abstract

Immune memory is essential for the effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. In the current context of the pandemic, with a diminished vaccine efficacy against emerging variants, it remains crucial to perform long-term studies to evaluate the durability and quality of immune responses. Here, we examined the antibody and memory B-cell responses in a cohort of 113 healthcare workers with distinct exposure histories over a 3-year period. Previously infected and naive participants developed comparable humoral responses by 17 months after receiving a full three-dose mRNA vaccination. In addition, both maintained a substantial SARS-CoV-2-reactive memory B-cell pool, associated with a lower incidence of breakthrough infections in naive participants. Of note, previously infected participants developed an expanded SARS-CoV-2-reactive CD27[SUP]-[/SUP]CD21[SUP]-[/SUP] atypical B-cell population that remained stable throughout the follow-up period. Thus, previous SARS-CoV-2 infection differentially imprints the memory B-cell compartment without compromising the development of long-lasting humoral responses.

Keywords: B cells; COVID-19; CP: Immunology; SARS-CoV-2; antibodies; atypical memory B cells; humoral immunology; immune memory; longitudinal cohorts.

 
Back
Top Bottom